[8696 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Cell Signaling Technology Inc anti akt antibodies
    Anti Akt Antibodies, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti akt antibodies/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti akt antibodies - by Bioz Stars, 2023-03
    95/100 stars
      Buy from Supplier

    520c9  (ATCC)
    93
    ATCC 520c9
    520c9, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/520c9/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    520c9 - by Bioz Stars, 2023-03
    93/100 stars
      Buy from Supplier

    86
    Probiodrug antibody 8696
    Antibody 8696, supplied by Probiodrug, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody 8696/product/Probiodrug
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    antibody 8696 - by Bioz Stars, 2023-03
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc vegfr2 kdr
    Vegfr2 Kdr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegfr2 kdr/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegfr2 kdr - by Bioz Stars, 2023-03
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc vegfr2
    Comparative analysis of VEGR2 and CD34 expressions in HCC tissues with different liver stiffness backgrounds. A. The expression levels of CD34 and <t>VEGFR2</t> in HCC tissues with normal liver stiffness background, medium liver stiffness background and high liver stiffness background. B. A comparative analysis of the average IOD value of CD34 and VEGFR2 expression in three groups of HCC tissues with different liver stiffness backgrounds by image pro-plus 6.0 software. In each case, error bars represent SD, *P<0.05, **P<0.01, ***P<0.001.
    Vegfr2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegfr2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegfr2 - by Bioz Stars, 2023-03
    86/100 stars
      Buy from Supplier

    Image Search Results


    Comparative analysis of VEGR2 and CD34 expressions in HCC tissues with different liver stiffness backgrounds. A. The expression levels of CD34 and VEGFR2 in HCC tissues with normal liver stiffness background, medium liver stiffness background and high liver stiffness background. B. A comparative analysis of the average IOD value of CD34 and VEGFR2 expression in three groups of HCC tissues with different liver stiffness backgrounds by image pro-plus 6.0 software. In each case, error bars represent SD, *P<0.05, **P<0.01, ***P<0.001.

    Journal: American Journal of Cancer Research

    Article Title: Integrin αVβ5/Akt/Sp1 pathway participates in matrix stiffness-mediated effects on VEGFR2 upregulation in vascular endothelial cells

    doi:

    Figure Lengend Snippet: Comparative analysis of VEGR2 and CD34 expressions in HCC tissues with different liver stiffness backgrounds. A. The expression levels of CD34 and VEGFR2 in HCC tissues with normal liver stiffness background, medium liver stiffness background and high liver stiffness background. B. A comparative analysis of the average IOD value of CD34 and VEGFR2 expression in three groups of HCC tissues with different liver stiffness backgrounds by image pro-plus 6.0 software. In each case, error bars represent SD, *P<0.05, **P<0.01, ***P<0.001.

    Article Snippet: Primary antibodies were diluted with 3% TBSA as follows: VEGFR2 (1:1000, Cell Signal Technology), Akt (1:1000, Cell Signal Technology), p-Akt (Ser473) (1:1000, Cell Signal Technology), Sp1 (1:1000, Cell Signal Technology), Integrin antibody sampler Kit (1:1000, Cell Signal Technology) and GAPDH (1:1000, Cell Signal Technology).

    Techniques: Expressing, Software

    Increased matrix stiffness actives AKT/Sp1 pathway and upregulates the expressions of VEGFR2 in HUVECs. A. mRNA expression level of VEGFR2 in HUVECs grown on 6 kPa stiffness substrate (L), 10 kPa stiffness substrate (M) and 16 kPa stiffness substrate (H). B. Protein expression level of VEGFR2 in HUVECs grown on 6 kPa stiffness substrate (L), 10 kPa stiffness substrate (M) and 16 kPa stiffness substrate (H). C. Higher matrix stiffness obviously elevates phosphorylation level of Akt in HUVECs. D. Higher matrix stiffness remarkably increased the expression of transcription factors Sp1 in HUVECs. E. Dual luciferase assay reveals an interaction between Sp1 and the promoter of gene VEGFR2.

    Journal: American Journal of Cancer Research

    Article Title: Integrin αVβ5/Akt/Sp1 pathway participates in matrix stiffness-mediated effects on VEGFR2 upregulation in vascular endothelial cells

    doi:

    Figure Lengend Snippet: Increased matrix stiffness actives AKT/Sp1 pathway and upregulates the expressions of VEGFR2 in HUVECs. A. mRNA expression level of VEGFR2 in HUVECs grown on 6 kPa stiffness substrate (L), 10 kPa stiffness substrate (M) and 16 kPa stiffness substrate (H). B. Protein expression level of VEGFR2 in HUVECs grown on 6 kPa stiffness substrate (L), 10 kPa stiffness substrate (M) and 16 kPa stiffness substrate (H). C. Higher matrix stiffness obviously elevates phosphorylation level of Akt in HUVECs. D. Higher matrix stiffness remarkably increased the expression of transcription factors Sp1 in HUVECs. E. Dual luciferase assay reveals an interaction between Sp1 and the promoter of gene VEGFR2.

    Article Snippet: Primary antibodies were diluted with 3% TBSA as follows: VEGFR2 (1:1000, Cell Signal Technology), Akt (1:1000, Cell Signal Technology), p-Akt (Ser473) (1:1000, Cell Signal Technology), Sp1 (1:1000, Cell Signal Technology), Integrin antibody sampler Kit (1:1000, Cell Signal Technology) and GAPDH (1:1000, Cell Signal Technology).

    Techniques: Expressing, Luciferase

    Integrin αV/β5/Akt/Sp1 pathway participates in matrix stiffness-mediated effects on VEGFR2 upregulation in HUVECs. A. Analysis of integrin subtypes in HUVECs under different stiffness stimulation. B. Antagonist SB273005 suppresses the phosphorylation level of Akt and VEGFR2 expression in HUVECs grown on 16 kPa stiffness substrate (H). C, D. siRNA against integrin αV or integrin β5 partially reverses the phosphorylation level of Akt and VEGFR2 expression in HUVECs grown on 16 kPa stiffness substrate (H). E. PI3K inhibitor LY294002 downregulates the phosphorylation level of Akt and the expressions of VEGFR2 and nuclear Sp1 in HUVECs grown on 16 kPa stiffness substrate (H).

    Journal: American Journal of Cancer Research

    Article Title: Integrin αVβ5/Akt/Sp1 pathway participates in matrix stiffness-mediated effects on VEGFR2 upregulation in vascular endothelial cells

    doi:

    Figure Lengend Snippet: Integrin αV/β5/Akt/Sp1 pathway participates in matrix stiffness-mediated effects on VEGFR2 upregulation in HUVECs. A. Analysis of integrin subtypes in HUVECs under different stiffness stimulation. B. Antagonist SB273005 suppresses the phosphorylation level of Akt and VEGFR2 expression in HUVECs grown on 16 kPa stiffness substrate (H). C, D. siRNA against integrin αV or integrin β5 partially reverses the phosphorylation level of Akt and VEGFR2 expression in HUVECs grown on 16 kPa stiffness substrate (H). E. PI3K inhibitor LY294002 downregulates the phosphorylation level of Akt and the expressions of VEGFR2 and nuclear Sp1 in HUVECs grown on 16 kPa stiffness substrate (H).

    Article Snippet: Primary antibodies were diluted with 3% TBSA as follows: VEGFR2 (1:1000, Cell Signal Technology), Akt (1:1000, Cell Signal Technology), p-Akt (Ser473) (1:1000, Cell Signal Technology), Sp1 (1:1000, Cell Signal Technology), Integrin antibody sampler Kit (1:1000, Cell Signal Technology) and GAPDH (1:1000, Cell Signal Technology).

    Techniques: Expressing

    VEGFR2 and CD34 expressions in TCGA-HCC tissues and their correlation with matrix stiffness. A. We defined the median expression of COL1A1 and LOX in TCGA-HCC tissues as the threshold to classify HCC patients into LOXhigh/COL1A1high group (45 patients) and LOXlow/COL1A1low group (44 patients), The mRNA expression level of VEGFR2 in TCGA-HCC tissues in LOXhigh/COL1A1high group (n=45) is obviously higher than that in LOXlow/COL1A1low group (n=44). B and C. Pearson correlation analysis indicates that the mRNA level of VEGFR2 in TCGA-HCC cohort is positively correlated with the mRNA level of COL1A1, while uncorrelated with that of LOX. D. The expression level of CD34 in HCC tissues LOXhigh/COL1A1high group (n=45) is significantly higher than that in LOXlow/COL1A1low group (n=44). E and F. Pearson correlation analysis indicates that the mRNA level of CD34 in TCGA-HCC cohort is positively correlated with that of both COL1A1 and LOX. **P<0.01, ****P<0.0001.

    Journal: American Journal of Cancer Research

    Article Title: Integrin αVβ5/Akt/Sp1 pathway participates in matrix stiffness-mediated effects on VEGFR2 upregulation in vascular endothelial cells

    doi:

    Figure Lengend Snippet: VEGFR2 and CD34 expressions in TCGA-HCC tissues and their correlation with matrix stiffness. A. We defined the median expression of COL1A1 and LOX in TCGA-HCC tissues as the threshold to classify HCC patients into LOXhigh/COL1A1high group (45 patients) and LOXlow/COL1A1low group (44 patients), The mRNA expression level of VEGFR2 in TCGA-HCC tissues in LOXhigh/COL1A1high group (n=45) is obviously higher than that in LOXlow/COL1A1low group (n=44). B and C. Pearson correlation analysis indicates that the mRNA level of VEGFR2 in TCGA-HCC cohort is positively correlated with the mRNA level of COL1A1, while uncorrelated with that of LOX. D. The expression level of CD34 in HCC tissues LOXhigh/COL1A1high group (n=45) is significantly higher than that in LOXlow/COL1A1low group (n=44). E and F. Pearson correlation analysis indicates that the mRNA level of CD34 in TCGA-HCC cohort is positively correlated with that of both COL1A1 and LOX. **P<0.01, ****P<0.0001.

    Article Snippet: Primary antibodies were diluted with 3% TBSA as follows: VEGFR2 (1:1000, Cell Signal Technology), Akt (1:1000, Cell Signal Technology), p-Akt (Ser473) (1:1000, Cell Signal Technology), Sp1 (1:1000, Cell Signal Technology), Integrin antibody sampler Kit (1:1000, Cell Signal Technology) and GAPDH (1:1000, Cell Signal Technology).

    Techniques: Expressing

    Associations of  VEGFR2  expression with clinicopathologic characteristics in HCC patients

    Journal: American Journal of Cancer Research

    Article Title: Integrin αVβ5/Akt/Sp1 pathway participates in matrix stiffness-mediated effects on VEGFR2 upregulation in vascular endothelial cells

    doi:

    Figure Lengend Snippet: Associations of VEGFR2 expression with clinicopathologic characteristics in HCC patients

    Article Snippet: Primary antibodies were diluted with 3% TBSA as follows: VEGFR2 (1:1000, Cell Signal Technology), Akt (1:1000, Cell Signal Technology), p-Akt (Ser473) (1:1000, Cell Signal Technology), Sp1 (1:1000, Cell Signal Technology), Integrin antibody sampler Kit (1:1000, Cell Signal Technology) and GAPDH (1:1000, Cell Signal Technology).

    Techniques: Expressing

    Correlation analysis between liver matrix stiffness and the VEGFR2/CD34 expression in HCC tissues. A. VEGFR2 and CD34 all exhibit obviously higher expression in LOXhigh/COL1A1high group compared to in LOXlow/COL1A1low group. ****P<0.0001. B. Representative images of immunohistochemistry staining of COL1A1, LOX, VEGFR2 and CD34.

    Journal: American Journal of Cancer Research

    Article Title: Integrin αVβ5/Akt/Sp1 pathway participates in matrix stiffness-mediated effects on VEGFR2 upregulation in vascular endothelial cells

    doi:

    Figure Lengend Snippet: Correlation analysis between liver matrix stiffness and the VEGFR2/CD34 expression in HCC tissues. A. VEGFR2 and CD34 all exhibit obviously higher expression in LOXhigh/COL1A1high group compared to in LOXlow/COL1A1low group. ****P<0.0001. B. Representative images of immunohistochemistry staining of COL1A1, LOX, VEGFR2 and CD34.

    Article Snippet: Primary antibodies were diluted with 3% TBSA as follows: VEGFR2 (1:1000, Cell Signal Technology), Akt (1:1000, Cell Signal Technology), p-Akt (Ser473) (1:1000, Cell Signal Technology), Sp1 (1:1000, Cell Signal Technology), Integrin antibody sampler Kit (1:1000, Cell Signal Technology) and GAPDH (1:1000, Cell Signal Technology).

    Techniques: Expressing, Immunohistochemistry, Staining

    The proposed mechanism by which matrix stiffness upregulates the expression of VEGFR2 in HUVECs via activating integrin αVβ5/Akt/Sp1 pathway.

    Journal: American Journal of Cancer Research

    Article Title: Integrin αVβ5/Akt/Sp1 pathway participates in matrix stiffness-mediated effects on VEGFR2 upregulation in vascular endothelial cells

    doi:

    Figure Lengend Snippet: The proposed mechanism by which matrix stiffness upregulates the expression of VEGFR2 in HUVECs via activating integrin αVβ5/Akt/Sp1 pathway.

    Article Snippet: Primary antibodies were diluted with 3% TBSA as follows: VEGFR2 (1:1000, Cell Signal Technology), Akt (1:1000, Cell Signal Technology), p-Akt (Ser473) (1:1000, Cell Signal Technology), Sp1 (1:1000, Cell Signal Technology), Integrin antibody sampler Kit (1:1000, Cell Signal Technology) and GAPDH (1:1000, Cell Signal Technology).

    Techniques: Expressing